Navigation Links
PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Date:11/6/2007

ANNAPOLIS, Md., Nov. 6 /PRNewswire-FirstCall/ -- PharmAthene (Amex: PIP), a biodefense company specializing in the development of medical countermeasures against biological and chemical threats, will webcast its third quarter 2007 financial results conference call on Tuesday, November 13, 2007 at 4:30 p.m. Eastern Time. David Wright, President and Chief Executive Officer and Christopher Camut, Vice President and Chief Financial Officer will review the Company's operations, business outlook and current financial results. A press release announcing the third quarter results will be issued at 4:00 p.m. E.T. on Tuesday, November 13, 2007, and be available on the Company's website.

Conference Call Information

To access the call, the dial-in number within the United States is 866-510-0676. The dial-in number for international callers is 617-597-5361. The participant passcode is 15368854.

Conference Call Replay

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. E.T. November 13th, 2007 until approximately 11:59 p.m. E.T. on December 13, 2007. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 84931672.

Webcast

The conference call will be also be webcast live and is accessible from the company's website at http://www.pharmathene.com. A link to the webcast may be accessed on the home page or under the 'Investor Relations' section of the website. The replay of the call will be available via webcast for 30 days, or until December 13, 2007.

About PharmAthene, Inc.

PharmAthene is a biodefense company formed in 2001 to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and
'/>"/>

SOURCE PharmAthene
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Biopure Announces 2007 Third Quarter Financial Results
4. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
5. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
6. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
7. Pharmacopeia Announces Third Quarter 2007 Financial Results
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 2Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 3Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 4Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 5Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Combo Therapies to Lower Cholesterol Dont Work 56054 1Combo Therapies to Lower Cholesterol Dont Work 56054 2Wounded Warrior Project to Participate in BGC Partners Annual Charity Day 56052 1Wounded Warrior Project to Participate in BGC Partners Annual Charity Day 56052 2Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease 13806 1Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease 13806 2Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease 13806 3Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease 13806 4